{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:12:59Z","timestamp":1788358379253,"version":"build-2803163510"},"reference-count":96,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["10932"],"award-info":[{"award-number":["10932"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Over the last decades, primary prostate cancer radiotherapy saw improving developments, such as more conformal dose administration and hypofractionated treatment regimens. Still, prostate cancer recurrences after whole-gland radiotherapy remain common, especially in patients with intermediate- to high-risk disease. The vast majority of these patients are treated palliatively with androgen deprivation therapy (ADT), which exposes them to harmful side-effects and is only effective for a limited amount of time. For patients with a localized recurrent tumor and no signs of metastatic disease, local treatment with curative intent seems more rational. However, whole-gland salvage treatments such as salvage radiotherapy or salvage prostatectomy are associated with significant toxicity and are, therefore, uncommonly performed. Treatments that are solely aimed at the recurrent tumor itself, thereby better sparing the surrounding organs at risk, potentially provide a safer salvage treatment option in terms of toxicity. To achieve such tumor-targeted treatment, imaging developments have made it possible to better exclude metastatic disease and accurately discriminate the tumor. Currently, focal salvage treatment is being performed with different modalities, including brachytherapy, cryotherapy, high-intensity focused ultrasound (HIFU), and stereotactic body radiation therapy (SBRT). Oncologic outcomes seem comparable to whole-gland salvage series, but with much lower toxicity rates. In terms of oncologic control, these results will improve further with better understanding of patient selection. Other developments, such as high-field diagnostic MRI and live adaptive MRI-guided radiotherapy, will further improve precision of the treatment.<\/jats:p>","DOI":"10.3390\/cancers10120480","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T06:02:09Z","timestamp":1543816929000},"page":"480","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1886-6385","authenticated-orcid":false,"given":"Marieke","family":"Van Son","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7981-5768","authenticated-orcid":false,"given":"Max","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinus","family":"Moerland","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Kerkmeijer","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lagendijk","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochem","family":"Van der Voort van Zyp","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,12,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"Eau-estro-siog guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1001\/jama.2012.460","article-title":"Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer","volume":"307","author":"Sheets","year":"2012","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4103\/0971-6203.189490","article-title":"Analysis of dose distribution in organs at risk in patients with prostate cancer treated with the intensity-modulated radiation therapy and arc technique","volume":"41","author":"Biegala","year":"2016","journal-title":"J. Med. Phys."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S1470-2045(14)70482-6","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Acute toxicity results from a randomised non-inferiority phase 3 trial","volume":"16","author":"Aluwini","year":"2015","journal-title":"Lancet. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Late toxicity results from a randomised, non-inferiority, phase 3 trial","volume":"17","author":"Aluwini","year":"2016","journal-title":"Lancet. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.radonc.2015.12.020","article-title":"Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials","volume":"118","author":"Musunuru","year":"2016","journal-title":"Radiother. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/14737140.2018.1477595","article-title":"How will the CHHiP trial affect the future of prostate radiotherapy?","volume":"18","author":"Dearnaley","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2011.10827.x","article-title":"Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the prostate cancer results study group","volume":"109","author":"Grimm","year":"2012","journal-title":"BJU Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.clon.2013.04.009","article-title":"Brachytherapy: Current status and future strategies-can high dose rate replace low dose rate and external beam radiotherapy?","volume":"25","author":"Morton","year":"2013","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Prada, P.J., Ferri, M., Cardenal, J., Blanco, A.G., Anchuelo, J., Diaz de Cerio, I., Vazquez, A., Pacheco, M., Raba, I., and Ruiz, S. (2018). High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 gy for the treatment of localized prostate cancer: Toxicity and 6-year biochemical results. Brachytherapy.","DOI":"10.1016\/j.brachy.2018.06.002"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","article-title":"Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): An analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Morris","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.eururo.2014.09.028","article-title":"The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy","volume":"67","author":"Zumsteg","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0090-4295(02)01728-4","article-title":"Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens","volume":"60","author":"Wise","year":"2002","journal-title":"Urology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.humpath.2010.02.011","article-title":"Multifocal prostate cancer: Biologic, prognostic, and therapeutic implications","volume":"41","author":"Andreoiu","year":"2010","journal-title":"Hum. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nm.1944","article-title":"Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer","volume":"15","author":"Liu","year":"2009","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMcibr0905562","article-title":"The index lesion and the origin of prostate cancer","volume":"361","author":"Ahmed","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_20","first-page":"632","article-title":"Will focal therapy become a standard of care for men with localized prostate cancer? Nature clinical practice","volume":"4","author":"Ahmed","year":"2007","journal-title":"Oncology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e787","DOI":"10.1016\/j.ijrobp.2011.11.030","article-title":"Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study","volume":"82","author":"Arrayeh","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0360-3016(02)02795-5","article-title":"Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: Implications for conformal therapy planning","volume":"53","author":"Cellini","year":"2002","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/j.ijrobp.2011.05.035","article-title":"Pathological predictors for site of local recurrence after radiotherapy for prostate cancer","volume":"82","author":"Chopra","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijrobp.2007.03.065","article-title":"Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: Magnetic resonance imaging and step-section pathology evidence","volume":"69","author":"Pucar","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.juro.2015.04.111","article-title":"Patterns of local failure following radiation therapy for prostate cancer","volume":"194","author":"Jalloh","year":"2015","journal-title":"J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2012.01.022","article-title":"Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: A systematic review of the literature","volume":"61","author":"Chade","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2012.07.008","article-title":"Salvage cryosurgery of the prostate for failure after primary radiotherapy or cryosurgery: Long-term clinical, functional, and oncologic outcomes in a large cohort at a tertiary referral centre","volume":"64","author":"Wenske","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2010.12.012","article-title":"Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer","volume":"60","author":"Williams","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.eururo.2008.04.091","article-title":"Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer","volume":"55","author":"Murat","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.radonc.2012.09.014","article-title":"Locally recurrent prostate cancer after initial radiation therapy: Early salvage high-intensity focused ultrasound improves oncologic outcomes","volume":"105","author":"Crouzet","year":"2012","journal-title":"Radiother. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijrobp.2013.01.027","article-title":"Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes","volume":"86","author":"Chen","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.brachy.2017.07.013","article-title":"Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time","volume":"16","author":"Kollmeier","year":"2017","journal-title":"Brachytherapy"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.radonc.2016.04.032","article-title":"Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after primary radiotherapy failure","volume":"119","author":"Wojcieszek","year":"2016","journal-title":"Radiother. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00345-012-0928-8","article-title":"Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: A multi-center experience and literature review","volume":"31","author":"Peters","year":"2013","journal-title":"World J. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.urolonc.2013.12.014","article-title":"Underutilization of local salvage therapy after radiation therapy for prostate cancer","volume":"32","author":"Tran","year":"2014","journal-title":"Urol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cncr.23161","article-title":"Cancer of the Prostate Strategic Urological Research, E. Treatment failure after primary and salvage therapy for prostate cancer: Likelihood, patterns of care, and outcomes","volume":"112","author":"Agarwal","year":"2008","journal-title":"Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1097\/01.ju.0000123981.03084.06","article-title":"Baseline staging of newly diagnosed prostate cancer: A summary of the literature","volume":"171","author":"Abuzallouf","year":"2004","journal-title":"J. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: A meta-analysis","volume":"63","author":"Hovels","year":"2008","journal-title":"Clin. Radiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.eururo.2012.09.039","article-title":"Utility of choline positron emission tomography\/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: A systematic literature review and meta-analysis","volume":"63","author":"Evangelista","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/RLU.0b013e3182867f3c","article-title":"Choline pet or PET\/CT and biochemical relapse of prostate cancer: A systematic review and meta-analysis","volume":"38","author":"Evangelista","year":"2013","journal-title":"Clin. Nucl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1148\/rg.2017170035","article-title":"Clinical pet imaging in prostate cancer","volume":"37","author":"Wallitt","year":"2017","journal-title":"Radiographics"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: A systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of pet imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"Zechmann","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumor lesions","volume":"40","author":"Malcher","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jamaoncol.2017.0287","article-title":"Prostate-specific membrane antigen positron emission tomography\/computed tomography in locally advanced, recurrent, and metastatic prostate cancer","volume":"4","author":"Perera","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1007\/s00259-018-4058-4","article-title":"Prospective comparison of (68)Ga-PSMA PET\/CT, (18)F-sodium fluoride PET\/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer","volume":"45","author":"Zacho","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cct.2015.07.004","article-title":"The forecast study-focal recurrent assessment and salvage treatment for radiorecurrent prostate cancer","volume":"44","author":"Kanthabalan","year":"2015","journal-title":"Contemp. Clin. Trials"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.eururo.2015.01.013","article-title":"Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature","volume":"68","author":"Futterer","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.eururo.2014.08.079","article-title":"Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: Correlation with whole-mount histopathology","volume":"67","author":"Le","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ijrobp.2007.06.029","article-title":"Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy","volume":"70","author":"Haider","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"W361","DOI":"10.2214\/AJR.12.9106","article-title":"Comparative sensitivities of functional MRI sequences in detection of local recurrence of prostate carcinoma after radical prostatectomy or external-beam radiotherapy","volume":"200","author":"Roy","year":"2013","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/j.1464-410X.2010.09291.x","article-title":"Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy","volume":"106","author":"Arumainayagam","year":"2010","journal-title":"BJU Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.rcl.2017.10.008","article-title":"Prostate MR imaging for posttreatment evaluation and recurrence","volume":"56","author":"Gaur","year":"2018","journal-title":"Radiol. Clin. North. Am."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/2156-7514.181494","article-title":"Multiparametric magnetic resonance imaging of recurrent prostate cancer","volume":"6","author":"Oppenheimer","year":"2016","journal-title":"J. Clin. Imaging Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.urolonc.2016.01.004","article-title":"Magnetic resonance imaging for localization of prostate cancer in the setting of biochemical recurrence","volume":"34","author":"Panebianco","year":"2016","journal-title":"Urol. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1148\/rg.2018170147","article-title":"Multiparametric MR imaging of the prostate after treatment of prostate cancer","volume":"38","author":"Patel","year":"2018","journal-title":"Radiographics"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Hotker, A.M., Meier, A., Mazaheri, Y., Zheng, J., Capanu, M., Chaim, J., Sosa, R., Coleman, J., Hricak, H., and Akin, O. (2018). Temporal changes in MRI appearance of the prostate after focal ablation. Abdom. Radiol.","DOI":"10.1007\/s00261-018-1715-9"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.2214\/AJR.17.18881","article-title":"Effect of combined (68)Ga-PSMAHBED-CC uptake pattern and multiparametric MRI derived with simultaneous PET\/MRI in the diagnosis of primary prostate cancer: Initial experience","volume":"210","author":"Taneja","year":"2018","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"Avtzi","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.eururo.2018.03.030","article-title":"Impact of (68)Ga-PSMA PET on the management of patients with prostate cancer: A systematic review and meta-analysis","volume":"74","author":"Han","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bju.13090","article-title":"Combination of multiparametric MRI and transperineal template-guided mapping biopsy of the prostate to identify candidates for hemi-ablative focal therapy","volume":"117","author":"Tran","year":"2016","journal-title":"BJU Int."},{"key":"ref_65","first-page":"e699","article-title":"The future trial; a multicenter RCT on three techniques of MRI targeted prostate biopsy","volume":"17","author":"Wegelin","year":"2018","journal-title":"EAU"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0360-3016(00)00637-4","article-title":"Postradiotherapy prostate biopsies: What do they really mean? Results for 498 patients","volume":"48","author":"Crook","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.eururo.2017.12.017","article-title":"Two-years postradiotherapy biopsies: Lessons from mrc rt01 trial","volume":"73","author":"Jovic","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clon.2016.04.038","article-title":"Transperineal magnetic resonance imaging-targeted biopsy versus transperineal template prostate mapping biopsy in the detection of localized radio-recurrent prostate cancer","volume":"28","author":"Kanthabalan","year":"2016","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/(SICI)1097-0142(19970101)79:1<81::AID-CNCR12>3.0.CO;2-2","article-title":"Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma","volume":"79","author":"Crook","year":"1997","journal-title":"Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/ajcp\/110.6.765","article-title":"The histology of radiation therapy effect on prostate adenocarcinoma as assessed by needle biopsy after brachytherapy boost. Correlation with biochemical failure","volume":"110","author":"Goldstein","year":"1998","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/1097-0142(19950401)75:7+<1837::AID-CNCR2820751613>3.0.CO;2-S","article-title":"Histologic effects of radiation therapy and total androgen blockade on prostate cancer","volume":"75","author":"Grignon","year":"1995","journal-title":"Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/bju.12151","article-title":"Salvage focal and salvage total cryoablation for locally recurrent prostate cancer after primary radiation therapy","volume":"112","author":"Bahn","year":"2013","journal-title":"BJU Int."},{"key":"ref_73","first-page":"810","article-title":"Salvage focal cryosurgery may delay use of androgen deprivation therapy in cryotherapy and radiation recurrent prostate cancer patients","volume":"33","author":"Kongnyuy","year":"2017","journal-title":"Int. J. Hyperthermia."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pros.22881","article-title":"Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: Initial results from the cryo on-line data registry","volume":"75","author":"Li","year":"2015","journal-title":"Prostate"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/bju.13831","article-title":"Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer","volume":"120","author":"Kanthabalan","year":"2017","journal-title":"BJU Int."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5114\/jcb.2016.60452","article-title":"Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature","volume":"8","author":"Kunogi","year":"2016","journal-title":"J. Contemp. Brachytherapy"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.radonc.2014.06.013","article-title":"Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: A retrospective study regarding toxicity, biochemical outcome and quality of life","volume":"112","author":"Peters","year":"2014","journal-title":"Radiother. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5114\/jcb.2016.61067","article-title":"Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer","volume":"8","author":"Zamboglou","year":"2016","journal-title":"J. Contemp. Brachytherapy"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1177\/1533034617741797","article-title":"Focal MRI-guided salvage high-dose-rate brachytherapy in patients with radiorecurrent prostate cancer","volume":"16","author":"Maenhout","year":"2017","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ijrobp.2018.06.039","article-title":"Focal salvage high dose-rate brachytherapy for locally recurrent prostate cancer after primary radiation therapy failure: Results from a prospective clinical trial","volume":"102","author":"Murgic","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ijrobp.2010.11.031","article-title":"Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer","volume":"82","author":"Beltramo","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13014-017-0789-9","article-title":"Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy","volume":"12","author":"Mbeutcha","year":"2017","journal-title":"Radiat. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11934-017-0709-4","article-title":"Salvage therapy options for local prostate cancer recurrence after primary radiotherapy: A literature review","volume":"18","author":"Golbari","year":"2017","journal-title":"Curr. Urol. Rep."},{"key":"ref_84","first-page":"264","article-title":"Salvage local therapy for radiation-recurrent prostate cancer-where are we?","volume":"69","author":"Zdrojowy","year":"2016","journal-title":"Cent. European J. Urol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00345-016-1811-9","article-title":"Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: A comprehensive review","volume":"34","author":"Duijzentkunst","year":"2016","journal-title":"World J. Urol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","article-title":"Simultaneous (68)Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer","volume":"70","author":"Eiber","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.radonc.2015.10.021","article-title":"A delphi consensus study on salvage brachytherapy for prostate cancer relapse after radiotherapy, a Uro-GEC study","volume":"118","author":"Kaljouw","year":"2016","journal-title":"Radiother. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"13.e1","DOI":"10.1016\/j.urolonc.2017.08.022","article-title":"Development and internal validation of prediction models for biochemical failure and composite failure after focal salvage high intensity focused ultrasound for local radiorecurrent prostate cancer: Presentation of risk scores for individual patient prognoses","volume":"36","author":"Peters","year":"2018","journal-title":"Urol. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Barret, E., Turkbey, B., Puech, P., Durand, M., Panebianco, V., Futterer, J.J., Renard-Penna, R., and Rouviere, O. (2018). Update on the ICUD-SIU consultation on multi-parametric magnetic resonance imaging in localized prostate cancer. World J. Urol.","DOI":"10.1007\/s00345-018-2395-3"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/MOU.0000000000000539","article-title":"Focal therapy for prostate cancer: Concepts and future directions","volume":"28","author":"Ashrafi","year":"2018","journal-title":"Curr. Opin. Urol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/RLI.0000000000000342","article-title":"Feasibility of multiparametric magnetic resonance imaging of the prostate at 7 T","volume":"52","author":"Lagemaat","year":"2017","journal-title":"Invest. Radiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.media.2017.04.001","article-title":"Learning non-rigid deformations for robust, constrained point-based registration in image-guided mr-trus prostate intervention","volume":"39","author":"Onofrey","year":"2017","journal-title":"Med. Image Anal."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Tharmalingam, H., Alonzi, R., and Hoskin, P.J. (2018). The role of magnetic resonance imaging in brachytherapy. Clin. Oncol. (R. Coll. Radiol.).","DOI":"10.1016\/j.clon.2018.07.024"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"N133","DOI":"10.1088\/0031-9155\/55\/5\/N02","article-title":"MRI-guided robotic system for transperineal prostate interventions: Proof of principle","volume":"55","author":"Moman","year":"2010","journal-title":"Phys. Med. Biol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"7567","DOI":"10.1088\/0031-9155\/60\/19\/7567","article-title":"An automated optimization tool for high-dose-rate (HDR) prostate brachytherapy with divergent needle pattern","volume":"60","author":"Maenhout","year":"2015","journal-title":"Phys. Med. Biol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1002\/mp.12467","article-title":"Fast online replanning for interfraction rotation correction in prostate radiotherapy","volume":"44","author":"Kontaxis","year":"2017","journal-title":"Med. Phys."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/12\/480\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:30:46Z","timestamp":1760196646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/12\/480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,3]]},"references-count":96,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["cancers10120480"],"URL":"https:\/\/doi.org\/10.3390\/cancers10120480","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,3]]}}}